Cargando…

PB1934: MEASURED OPTIMUM ANTI-SPIKE LEVEL VACCINATION STRATEGY AND ANTI-VIRAL ACCESS RESULT IN LOW COVID HOSPITALISATION AND MORTALITY IN CLL AND MBL

Detalles Bibliográficos
Autores principales:	Shen, Yandong, Freeman, Jane, Kerridge, Ian, Naidu, Kartik, Holland, Juliette, Mulligan, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430022/ http://dx.doi.org/10.1097/01.HS9.0000974556.83221.a1

Ejemplares similares

Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
por: Shen, Yandong, et al.
Publicado: (2022)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

PB1911: CYTOGENOMIC INTEGRATIVE ANALYSIS OF CLL/SLL PATIENTS AT DISEASE PROGRESSION.
por: García-Serra, Rocío, et al.
Publicado: (2023)

PB1950: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1866: RESPONSE TO NOVEL ANTI CD20 ANTIBODY AND BCL2 INHIBITOR IN A PATIENT WITH CLL AND MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS ASSOCIATED WITH LEUKEMIC KIDNEY INFILTRATION AND REVIEW OF LITERATURE
por: Goanta, J. G., et al.
Publicado: (2022)

PB1934: REAL-WORLD OUTCOMES OF ECULIZUMAB TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINUREA: A SYSTEMATIC LITERATURE REVIEW AND EVIDENCE SYNTHESIS
por: Nishimura, J.-I., et al.
Publicado: (2022)

PB1945: PATIENT PERSPECTIVES ON CLL TREATMENT SIDE EFFECTS: A SUB-ANALYSIS OF THE VOICE SURVEY
por: Tam, Constantine, et al.
Publicado: (2023)

PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
por: Qerama, Shaqir, et al.
Publicado: (2023)

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
por: Allan, J. N., et al.
Publicado: (2022)

PB2328: CHRONIC LYMPHATIC LEUKAEMIA (CLL) ASSOCIATED TO ACQUIRED FACTOR V INHIBITOR. A CASE REPORT.
por: Porro Camarero, A., et al.
Publicado: (2022)

PB1936: IDENTIFYING INEQUITIES IN SUPPORT - GLOBAL SURVEY OF PATIENT ORGANISATIONS DELIVERING SUPPORT SERVICES FOR CLL PATIENTS
por: Baker, Deborah, et al.
Publicado: (2023)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION
por: László, Tamás, et al.
Publicado: (2023)

PB1931: LOW SERUM CHOLESTEROL LEVEL AS A SIGNIFICANT PROGNOSTIC FACTOR IMPROVES CLL-IPI IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Gao, Rui, et al.
Publicado: (2023)

PB1881: IBRUTINIB REDUCES THE RISK OF RICHTER’S TRANSFORMATION IN PREVIOUSLY TREATED CLL PATIENTS: A POPULATION-BASED STUDY IN BRITISH COLUMBIA
por: Ramadan, R., et al.
Publicado: (2022)

PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS – DATA FROM THE OBSERVATIONAL STUDY VERVE
por: Schwaner, Ingo, et al.
Publicado: (2023)

PB1923: NON-HEMATOLOGIC AUTOIMMUNE DISORDERS IN CLL: PREVALENCE AND PROGNOSTIC IMPACT IN A REAL-LIFE COHORT FROM A SINGLE-CENTRE
por: De Tomás, Miguel Argüello, et al.
Publicado: (2023)

PB1949: ROLE OF LAIR1 (CD305) IN FLOW CYTOMETRIC DETECTION OF OCCULT BONE MARROW INVOLVEMENT IN NON-CLL B-CELL NON-HODGKIN LYMPHOMA
por: Ghogale, Sitaram, et al.
Publicado: (2023)

PB1715: UNLEASHING NATURAL KILLER (NK) CELLS TO PROMOTE ANTI-LEUKEMIC IMMUNITY
por: Tsoukala, Ioanna, et al.
Publicado: (2023)

PB1829: QUERCETIN EXHIBITS ANTI-LEUKEMIA EFFECTS VIA REGULATION OF METABOLIC REPROGRAMMING
por: Zhang, Jing, et al.
Publicado: (2023)

PB1924: INCIDENCE OF CARDIOVASCULAR AND BLEEDING EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) TREATED WITH IBRUTINIB – A RETROSPECTIVE ANALYSIS ON CONSECUTIVE PATIENTS FROM A WELL-DEFINED REGION.
por: Andersson, Maria, et al.
Publicado: (2023)

PB2697: LONG TERM PEJORATIVE IMPACT OF LENALIDOMIDE MAINTENANCE ON HEALTH-RELATED QUALITY OF LIFE IN CHRONIC LYMPHOCYTIC LEUKEMIA. ANCILLARY STUDY OF THE PHASE III CLL6-RESIDUUM TRIAL
por: Wasse, Stephane, et al.
Publicado: (2023)

PB2514: IMMUNOGENICITY OF ANTI-SARS-COV-2 VACCINES IN PATIENTS WITH SEVERE SICKLE CELL DISEASE
por: Meunier, Benoit, et al.
Publicado: (2023)

PB1843: DONOR-DERIVED CLL-1 CHIMERIC ANTIGEN RECEPTOR T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BRIDGING TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT
por: Miao, Xiaojuan, et al.
Publicado: (2023)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
por: Barrientos, J. C., et al.
Publicado: (2022)

PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)
por: Jurczak, W., et al.
Publicado: (2022)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

PB1973: INHIBITION OF LACTATE EXPORTERS INDUCES DIRECT ANTI-TUMOR EFFECTS AND COUNTERS IMMUNE SUPPRESSION IN MULTIPLE MYELOMA
por: Van der Vreken, A., et al.
Publicado: (2022)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
por: Valdes, Cesar Rodriguez, et al.
Publicado: (2023)

PB2696: QUALITATIVE INTERVIEWS TO DESCRIBE BURDEN IN PATIENTS (PT) WITH THIRD-LINE OR LATER CLL/SLL WITH PRIOR EXPOSURE TO BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
por: Priyadarshini, Masoom, et al.
Publicado: (2023)

PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY.
por: Catania, Federica, et al.
Publicado: (2023)

PB1778: PAN-PIM KINASE INHIBITOR PIM447 SHOWS SUPERIOR ANTI-LEUKEMIC EFFECT IN ACUTE ERYTHROID LEUKEMIA
por: Tseng, Chi-Yang, et al.
Publicado: (2023)

PB2286: INFLUENCE OF ANTI-CD20 MONOCLONAL ANTIBODY THERAPY ON THE OUTCOME OF CORONAVIRUS INFECTION COVID-19 IN PATIENTS WITH LYMPHOPROLIFERATIVE DISEASES
por: Zotina, E., et al.
Publicado: (2022)

PB2682: ANTI-NEOPLASTIC TREATMENT, BASED ON PRO DATA REPORTED THROUGH A MHEALTH APP SOLUTION IN MULTIPLE MYELOMA PATIENTS
por: Kirkegaard, Jannie
Publicado: (2023)

PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Mohammed, Turab, et al.
Publicado: (2023)

PB2205: ANTI-INFLAMMATORY AND REGENERATIVE EFFECTS OF UMBILICAL CORD BLOOD ENDOTHELIAL PROGENITOR CELL-DERIVED EXTRACELLULAR VESICLES ON ENDOTHELIAL CELLS IN VITRO
por: Ben Fraj, S., et al.
Publicado: (2022)

PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT
por: Varelas, Christos, et al.
Publicado: (2023)

PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

Platelet thrombus formation in eHUS is prevented by anti-MBL2
por: Kushak, R. I., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uq1e3j35psd1lhps19ca8g186f